{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:48Z","timestamp":1789154508728,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,19]]},"DOI":"10.7759\/cureus.79338","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:56:56Z","timestamp":1740038216000},"source":"Crossref","is-referenced-by-count":1,"title":["Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, and Somatic (VEXAS) Syndrome: A Diagnostic and Therapeutic Conundrum"],"prefix":"10.7759","author":[{"given":"Sofia","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Roias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Rua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011455","article-title":"VEXAS syndrome","volume":"137","author":"Grayson PC","year":"2021","unstructured":"Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021, 137:3591-4. 10.1182\/blood.2021011455","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck DB","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V, et al.. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA. 2023, 329:318-24. 10.1001\/jama.2022.24836","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck DB","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, et al.. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020, 383:2628-38. 10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada MA","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, et al.. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022, 140:1496-506. 10.1182\/blood.2022016985","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2157262","article-title":"An update on VEXAS syndrome","volume":"19","author":"Al-Hakim A","year":"2023","unstructured":"Al-Hakim A, Savic S. An update on VEXAS syndrome. Expert Rev Clin Immunol. 2023, 19:203-15. 10.1080\/1744666X.2023.2157262","journal-title":"Expert Rev Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle S","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, et al.. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022, 186:564-74. 10.1111\/bjd.20805","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003332","article-title":"VEXAS syndrome: a diagnostic puzzle","volume":"9","author":"Ruffer N","year":"2023","unstructured":"Ruffer N, Krusche M. VEXAS syndrome: a diagnostic puzzle. RMD Open. 2023, 9:e003332. 10.1136\/rmdopen-2023-003332","journal-title":"RMD Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: a\u00a0Dutch case series of patients with VEXAS","volume":"149","author":"van der Made CI","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, et al.. Adult-onset autoinflammation caused by somatic mutations in UBA1: a\u00a0Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022, 149:432-9.e4. 10.1016\/j.jaci.2021.05.014","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva Z","year":"2023","unstructured":"Boyadzhieva Z, Ruffer N, K\u00f6tter I, Krusche M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023, 62:3518-25. 10.1093\/rheumatology\/kead240","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16635","article-title":"Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings","volume":"62","author":"Hines AS","year":"2023","unstructured":"Hines AS, Mohandesi NA, Lehman JS, et al.. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. Int J Dermatol. 2023, 62:938-45. 10.1111\/ijd.16635","journal-title":"Int J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard E","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, et al.. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022, 1:EVIDoa2200008. 10.1056\/EVIDoa2200008","journal-title":"NEJM Evid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig M","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MJ, et al.. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022, 140:927-31. 10.1182\/blood.2022016642","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/341780-vacuoles-e1-enzyme-x-linked-autoinflammatory-and-somatic-vexas-syndrome-a-diagnostic-and-therapeutic-conundrum","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:56:58Z","timestamp":1740038218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/341780-vacuoles-e1-enzyme-x-linked-autoinflammatory-and-somatic-vexas-syndrome-a-diagnostic-and-therapeutic-conundrum"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.79338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}